Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 5/20 | 0.55 |
| ▸ | CA1 | P00915 | 4/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7174070 | 0.94 | TSHR (0.58) | LOXL2RAB9ANPC1CYP4A11TSHR | |
| SCHEMBL22664443 | 0.88 | LOXL2 (0.51) | LOXL2RAB9ANPC1CYP4A11TSHR | |
| SCHEMBL30455896 | 0.88 | LOXL2 (0.54) | LOXL2RAB9ANPC1CYP4A11TSHR | |
| SCHEMBL20259350 | 0.86 | LOXL2 (0.66) | LOXL2RAB9ANPC1CYP4A11TSHR | |
| SCHEMBL1811746 | 0.85 | LOXL2 (0.59) | LOXL2RAB9ANPC1CYP4A11TSHR | |
| SCHEMBL7151482 | 0.84 | LOXL2 (0.63) | LOXL2RAB9ANPC1CYP4A11TSHR | |
| SCHEMBL1198228 | 0.84 | LOXL2 (0.63) | LOXL2RAB9ANPC1CYP4A11TSHR | |
| SCHEMBL11845435 | 0.83 | CA2 (0.56) | TSHRKMT2ACA2TDP1MAPT | |
| SCHEMBL11459316 | 0.83 | PTGS1 (0.64) | LOXL2CYP4A11TSHRCA2CA1 | |
| SCHEMBL1199408 | 0.82 | LOXL2 (0.61) | LOXL2RAB9ANPC1CYP4A11TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 303 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4142874-B1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RAQUALIA PHARMA INC (JP) | 2026-04-22 | — | — | EP | disclosed |
| US-20260085046-A1 | Dual Function Compounds For NADPH Oxidase Inhibition And Histone Deacetylase Inhibition | TAIWANJ PHARMACEUTICALS CO LTD (TW) | 2026-03-26 | — | — | US | disclosed |
| US-12479797-B2 | Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors | Jubilant Epicore LLC (US) | 2025-11-25 | — | — | US | disclosed |
| EP-3455204-B1 | CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS | Jubilant Epicore LLC (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4622964-A1 | QUINAZOLINONE DERIVATIVES FOR HDAC INHIBITION | Gilva Therapeutics Co., Ltd. (TW) | 2025-10-01 | — | — | EP | disclosed |
| EP-4240738-B1 | PYRAZOLE DERIVATIVES AS RET KINASE INHIBITORS | LILLY CO ELI (US) | 2025-05-07 | — | — | EP | disclosed |
| WO-2025085669-A1 | QUINAZOLINONE DERIVATIVES FOR HDAC INHIBITION | GILVA THERAPEUTICS CO., LTD. (CN) | 2025-04-24 | — | — | WO | disclosed |
| CN-116157398-B | Oxadiazole-based selective histone deacetylase 6 inhibitors | 意大发马克股份公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-115427409-B | Pyrimidine-4 (3H) -one derivatives as TRPV4 antagonists | 拉夸里亚创药株式会社 | 2025-02-25 | — | — | CN | disclosed |
| CN-119264128-A | Thiadiazole and pyridazine parent nucleus compound, preparation method and pharmaceutical application thereof | 中国医学科学院药物研究所 | 2025-01-07 | — | — | CN | disclosed |
| US-5273986-A | A substituted phenylalkyleneamidophenyleneethylene thiazole | HOFFMANN-LA ROCHE INC. (US) | 1993-12-28 | — | — | US | disclosed |
| US-5221760-A | Intermediates, leukotriene antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 1993-06-22 | — | — | US | disclosed |
| US-5159097-A | An arylphosphorous compound as chemical intermediate | BAYER AKTIENGESELLSCHAFT (DE) | 1992-10-27 | — | — | US | disclosed |
| EP-0509769-A2 | Heterocyclic amides having HLE inhibiting activity | ZENECA LIMITED (GB) | 1992-10-21 | — | — | EP | disclosed |
| EP-0341551-B1 | ALKENOIC ACID DERIVATIVES | BAYER AG (DE) | 1992-04-01 | — | — | EP | disclosed |
| US-5041638-A | Leucotriene antagonist; treatment of respiratory system disorders, cardiovascular disorders | BAYER AKTIENGESELLSCHAFT (DE) | 1991-08-20 | — | — | US | disclosed |
| EP-0341551-A1 | Alkenoic acid derivatives | BAYER AG (DE) | 1989-11-15 | — | — | EP | disclosed |
| US-4735959-A | HYPOGLYCEMIC AGENTS | DR. KARL THOMAE GMBH (DE) | 1988-04-05 | — | — | US | disclosed |
| EP-0058779-B1 | CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS MEDICINES | Dr. Karl Thomae GmbH (DE) | 1984-09-19 | — | — | EP | disclosed |
| EP-0058779-A2 | Carboxamides, their preparation and their use as medicines | Dr. Karl Thomae GmbH (DE) | 1982-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085046-A1 | Dual Function Compounds For NADPH Oxidase Inhibition And Histone Deacetylase Inhibition | NOX1, NOX4, CYBB | LOXL2 1013/4885RAB9A 1083/4885NPC1 2232/4885 |
| US-12479797-B2 | Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors | HDAC1, HDAC11, HDAC2 | LOXL2 839/4885RAB9A 1828/4885NPC1 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.